Loading…
← CockpitCompetitor Analysis › CLTN.SW COLTENE Holding AGOpen in the cockpit ↗

COLTENE Holding AGCLTN.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Medical Specialties
Momentum weak 27
Mkt cap
$339M
US dollars, full cap
Free float
43%
of shares outstanding
$/day
$95,408
20-day average traded
Fwd P/E
25.2×
forward earnings
ROIC−WACC
+6.7 pp
WACC 5.0%
Hurdle
+0 pp
Req g minus delivered
Next earnings
107 days
5 Mar 2027
Close · CHFCHF 47.80
1D-0.9%
1W-0.1%
1M-1.4%
3M0.0%
6M-7.0%
YTD-11.0%
1Y-1.6%
ATR %1.9%
52w lowhigh19.0% off high

What COLTENE does

Employees: 1,180

COLTENE at a glance

Size COLTENE (CLTN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $339M, the 151st largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 47.80 on 18 Nov 2026.

Performance Over six months the shares fell 7.0%, against -15.3% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 9th highest of 20 in its peer set.

Growth Revenue fell 2.5% over the last twelve months (peer median +7.0%); the operating margin is 7.9% (peer median 9.4%).

Valuation It trades at 25.2× forward earnings against a peer median of 17.5× (4th most expensive of 12).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 6.7 points above its cost of capital (5.0% WACC).

Next results Next results expected around 5 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026CLTN.SW 93Peer median 85
Six months, rebased to 100: COLTENE against the median of its 20 peers (local-currency closes).

COLTENE financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 235MCHF 240MCHF 250MCHF 243MCHF 267M
Revenue growth—-4%+3%-9%—
Gross profitCHF 58.9MCHF 61.5MCHF 67.7MCHF 59.7MCHF 78.3M
EBITDACHF 26.0MCHF 27.7MCHF 33.7MCHF 26.6MCHF 41.7M
Net incomeCHF 14.7MCHF 14.9MCHF 20.5MCHF 11.9MCHF 26.0M
Free cash flowCHF 14.5MCHF 9.17MCHF 23.8MCHF 19.1MCHF 17.9M
Capital expenditureCHF 6.63MCHF 6.08MCHF 5.75MCHF 8.68MCHF 8.32M
Total debtn/aCHF 47.0MCHF 40.0MCHF 45.0MCHF 47.1M

Quarterly statements and history in the cockpit →

COLTENE competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-20%0%+20%688273377740301502YDESEMBC197A688468VBSN3009423006536883381609SBSBWAY6748CLTN.SW6-month return →1-month return →
Up and to the right = strong over both horizons. COLTENE is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×250×500×750×688273377740EMBC197A3007535889688338BWAY300562CLTN.SWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. COLTENE is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%688273377740301502EMBC688468300753VBSN30065358896883381609BWAY3005622041CLTN.SWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. COLTENE is the large dot.

COLTENE competitors and peer comparison

How COLTENE compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

COLTENE against its 20 peers (data as of 18 Nov 2026)
MeasureCLTN.SWPeer medianRank in peer set
1-month return-1.4%-9.8%5th highest of 21
6-month return-7.0%-15.3%9th highest of 20
Distance from 52-week high-19.0%-45.3%4th highest of 21
Revenue growth (TTM)-2.5%+7.0%9th lowest of 21
Operating margin7.9%9.4%10th lowest of 21
Forward P/E25.2×17.5×4th most expensive of 12
Growth the price implies (Req g, 7 yrs)-0.3%15.8%7th least demanding of 16
Growth delivered (Del g)-0.7%+0.4%6th lowest of 16
Hurdle (Req g minus delivered)+0.4 pp+6.1 pp6th least demanding of 16
ROIC minus cost of capital+6.7 pp+0.6 pp9th highest of 19
EV / EBITDA12.3×8.3×4th most expensive of 11
Net debt / EBITDA1.3×-2.1×5th most indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
COLTENE CLTN.SWSwitzerland$339M-7%-2%8%25.2×-0.3%-0.7%
Nanjing Medlander Medical Technology 688273.SSChina$337M-47%-12%8%17.5×35.3%+5.2%
BioNote 377740.KSSouth Korea$337M-14%+12%18%14.4×-15.0%-28.5%
Jiangsu Huayang Intelligent Equipment 301502.SZChina$336M-36%-5%2%n/a34.3%+0.4%
YD Bio YDESUnited States$344M+7%+17%-883%n/an/an/a
Embecta EMBCUnited States$345M+99%-8%26%3.8×-19.9%-0.1%
Tauns Laboratories 197A.TJapan$327M-3%+7%29%16.7×n/an/a
Chemclin Diagnostics 688468.SSChina$327M-24%-10%4%n/a15.8%-4.5%
Jiangsu Apon Medical Technology 300753.SZChina$326M-34%-15%-10%862.0×20.0%-5.1%
IVF HARTMANN VBSN.SWSwitzerland$352M-2%+7%14%n/a-12.7%-1.3%
Shenzhen Bioeasy Biotechnology 300942.SZChina$326M-27%+12%-2%n/an/an/a
Yantai Zhenghai Bio-Tech 300653.SZChina$354M-23%-8%17%36.0×18.4%+4.4%
Japan Eyewear 5889.TJapan$318M-5%+15%32%10.7×-9.4%+20.2%
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%16.4×5.7%+3.4%
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%n/a-13.1%+36.8%
Stratec SBS.DEGermany$365M+63%-6%4%18.2×19.1%+0.1%
CapsoVision CVUnited States$366M+5%+15%-213%n/an/an/a
Brainsway Ltd Sponsored ADR BWAYUnited States$373M-41%+32%14%20.3×24.9%+18.8%
Guangdong Transtek Medical Electronics 300562.SZChina$373M-15%+7%11%25.3×-4.2%-6.0%
ACRO Biomedical 6748.TWOTaiwan$377M+158%+45%-178%n/an/an/a
Medcaptain Medical Technology 2041.HKHong Kong$378Mn/a+19%2%n/a17.1%+18.1%

Questions

Which companies are COLTENE's closest peers?
The cockpit's peer set: Nanjing Medlander Medical Technology (688273.SS), BioNote (377740.KS), Jiangsu Huayang Intelligent Equipment (301502.SZ), YD Bio (YDES), Embecta (EMBC), Tauns Laboratories (197A.T), Chemclin Diagnostics (688468.SS), Jiangsu Apon Medical Technology (300753.SZ).
Is COLTENE expensive compared with its peers?
On forward p/e it trades at 25.2× against a peer median of 17.5×, 4th most expensive of 12 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has COLTENE stock performed?
Over six months to 18 Nov 2026 the shares returned -7.0% against -15.3% for the median peer; over one year -1.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.